Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

PHASE2CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

December 3, 2020

Study Completion Date

December 3, 2020

Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
DRUG

OLAPARIB

300 mg olaparib tablets taken orally twice daily

Trial Locations (47)

10021

Research Site, New York

10032

Research Site, New York

10065

Research Site, New York

10461

Research Site, The Bronx

15224

Research Site, Pittsburgh

19001

Research Site, Abington

19104

Research Site, Philadelphia

19718

Research Site, Newark

20910

Research Site, Silver Spring

22003

Research Site, Annandale

27103

Research Site, Winston-Salem

33143

Research Site, South Miami

38138

Research Site, Germantown

45219

Research Site, Cincinnati

48201

Research Site, Detroit

48202

Research Site, Detroit

53226

Research Site, Milwaukee

55125

Research Site, Saint Paul

55407

Research Site, Minneapolis

60077

Research Site, Skokie

71103

Research Site, Shreveport

77030

Research Site, Houston

80045

Research Site, Aurora

90017

Research Site, Los Angeles

92093

Research Site, La Jolla

97227

Research Site, Portland

99508

Research Site, Anchorage

06102

Research Site, Hartford

06519

Research Site, New Haven

01199

Research Site, Springfield

07922

Research Site, Berkeley Heights

07601

Research Site, Hackensack

07103

Research Site, Newark

07666

Research Site, Teaneck

02905

Research Site, Providence

T6G 1Z2

Research Site, Edmonton

VSZ 4E6

Research Site, Vancouver

R3E 0V9

Research Site, Winnipeg

B3H 1V7

Research Site, Halifax

L8V 5C2

Research Site, Hamilton

K7L 2V7

Research Site, Kingston

L5M 2N1

Research Site, Mississauga

M4N 3M5

Research Site, Toronto

H1T 2M4

Research Site, Montreal

H2X 0A9

Research Site, Montreal

H4A 3J1

Research Site, Montreal

J1H 5N4

Research Site, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY